Tilray® Expands Medical Cannabis Product Offering in Australia to Include Whole Flower

Tilray’s complete product offering now the broadest medical cannabis offering from a Licensed Producer in the market

NANAIMO, B.C. –Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced the launch of four new products in Australia, expanding the company’s product offering to include both medical cannabis oral solution and whole flower and marking it as the broadest medical cannabis offering from an Licensed Producer in Australia.

Tilray is one of the leading providers of medical cannabis in Australia and New Zealand for commercial, compassionate access and research purposes and was the first Licensed Producer to legally export medical cannabis from North America to Australia and New Zealand from its Good Manufacturing Practices (GMP)-certified facility in Canada.

“We’re proud to broaden our offering to include both whole flower and oral solutions. This new product mix provides more Australian patients with access to a selection of consumption methods to suit their individual needs,” says Nicole Godresse, General Manager, Tilray Australia and New Zealand. “Tilray medical cannabis products are prescribed to qualified patients across the country including: adult and pediatric patients suffering from chronic illnesses and a number of other approved indications.”

Tilray’s new product offering now includes both whole flower and oral solutions in cannabidiol (CBD)-dominant, tetrahydrocannabinol (THC)-dominant and balanced varieties.

The new products include:

· Tilray®T1:C25FullSpectrumOralSolution

· Tilray®T5:C20FullSpectrumOralSolution

· Tilray® Whole Flower THC 25

· Tilray® Whole Flower THC 10: CBD 10

In addition to supplying hospitals and pharmacies,Tilray is also a proud partner with a number of leading research institutions in Australia. Trials currently underway include a study on the effectiveness of Tilray medical cannabis as treatment for pediatric patients with Intellectual Disabilities suffering from Severe Behavioral Problems; a clinical trial to develop a novel treatment for chemotherapy-induced nausea, and a study examining the effects of driving under the influence of cannabis.

Tilray looks forward to expanding its product offering further and supplying more patients in-need with high-quality medical cannabis products.

About Tilray®

Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 12 countries spanning 5 continents.

Cautionary note regarding forward-looking statements:

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements or forward-looking-information in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including without limitation statements in respect to Tilray’s product offering, future product offering, research capabilities and global operations. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission and Canadian securities regulators on May 15, 2019, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Tilray does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

/Public Release.